SBI Securities Co. Ltd. Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS)

SBI Securities Co. Ltd. acquired a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 72,280 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.

A number of other large investors have also modified their holdings of the stock. State Street Corp increased its position in shares of Arbutus Biopharma by 50.2% during the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock worth $16,967,000 after acquiring an additional 1,472,652 shares during the period. Geode Capital Management LLC increased its position in shares of Arbutus Biopharma by 4.1% during the third quarter. Geode Capital Management LLC now owns 3,448,600 shares of the biopharmaceutical company’s stock worth $13,280,000 after acquiring an additional 135,442 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Arbutus Biopharma by 218.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after acquiring an additional 831,663 shares during the period. Wellington Management Group LLP increased its position in shares of Arbutus Biopharma by 4.6% during the third quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company’s stock worth $1,913,000 after acquiring an additional 21,807 shares during the period. Finally, Barclays PLC increased its position in shares of Arbutus Biopharma by 466.3% during the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock worth $1,047,000 after acquiring an additional 223,995 shares during the period. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Price Performance

NASDAQ:ABUS opened at $3.46 on Thursday. The firm has a market capitalization of $655.64 million, a PE ratio of -8.05 and a beta of 1.93. The business’s fifty day moving average price is $3.33 and its 200 day moving average price is $3.65. Arbutus Biopharma Co. has a 12 month low of $2.30 and a 12 month high of $4.73.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABUS. Chardan Capital reaffirmed a “buy” rating and set a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. StockNews.com raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday. JMP Securities increased their target price on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.